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A b s t r a c t    
 
 
Background: Nicotinamide phosphoribosyltransferase (NAMPT) is the key enzyme of the NAD salvage 
pathway starting from nicotinamide. Cancer cells have an increased demand for NAD due to their high 
proliferation and DNA repair rate. Consequently, NAMPT is considered as a putative target for anti-cancer 
therapies. There is evidence that AMP-activated protein kinase (AMPK) and mammalian target of 
rapamycin (mTOR) become dysregulated during the development of hepatocellular carcinoma (HCC). 
Here, we investigated the effects of NAMPT inhibition by its specific inhibitor FK866 on the viability of 
hepatocarcinoma cells and analyzed the effects of FK866 on the nutrient sensor AMPK and mTOR 
complex1 (mTORC1) signaling. 
Results: FK866 markedly decreased NAMPT activity and NAD content in hepatocarcinoma cells (Huh7 
cells, Hep3B cells) and led to delayed ATP reduction which was associated with increased cell death. 
These effects could be abrogated by administration of nicotinamide mononucleotide (NMN), the enzyme 
product of NAMPT. Our results demonstrated a dysregulation of the AMPK/mTOR pathway in hep- 
atocarcinoma cells compared to non-cancerous hepatocytes with a higher expression of mTOR and a 
lower AMPKa activation in hepatocarcinoma cells. We found that NAMPT inhibition by FK866 signifi- 
cantly activated AMPKa and inhibited the activation of mTOR and its downstream targets p70S6 kinase 
and 4E-BP1 in hepatocarcinoma cells. Non-cancerous hepatocytes were less sensitive to FK866 and did 
not show changes in AMPK/mTOR signaling after FK866 treatment. 
Conclusion: Taken together, these findings reveal an important role of the NAMPT-mediated NAD salvage 
pathway in the energy homeostasis of hepatocarcinoma cells and suggest NAMPT inhibition as a po- 
tential treatment option for HCC.
 
 
 
1. Introduction 
 
 
 
Abbreviation: NAMPT, nicotinamide phosphoribosyltransferase; AMPK, 
AMP- activated protein kinase; mTOR, mammalian target of rapamycin; HCC, 
hepatocel- lular carcinoma; PHH, primary human hepatocytes; mTORC1, mTOR 
complex1; NMN, nicotinamide mononucleotide; p70S6 kinase, 70S 
ribosomal protein S6 ki- nase; 4E-BP1, eukaryotic initiation factor 4E binding 
protein 1; NAD, nicotinamide adenine dinucleotide; PARPs, poly(ADPeribose) 
polymerases; MARTs, mono-ADP ribosyltransferases; PI, propidium iodide; 
ATP, adenosine triphosphate; EDTA, ethylenediaminetetraacetic acid; TSA, 
trichostatin A; GAPDH, glyceraldehyde-3- phosphate dehydrogenase;  cpm,  
counts  per  minute. 
* Corresponding author. Fax: +49 341 97 26069. 
E-mail address: Susanne.Schuster@medizin.uni-leipzig.de (S. Schuster). 
1  Both authors contributed equally to this work. 
The co-factor nicotinamide adenine dinucleotide (NAD) plays 
a crucial role in multiple cellular processes and is substrate 
for a variety of enzymes and regulatory proteins [1]. In humans 
a main portion of NAD is generated via the nicotinamide 
(NAM) salvage pathway, in which nicotinamide 
phosphoribosyltransferase (NAMPT) catalyzes the rate-limiting 
step in the biosynthesis of NAD yielding nicotinamide 
mononucleotide (NMN) [2,3]. As NAD is rapidly consumed in 
cells (1 h) and converted to NAM [4], NAMPT is essential for the 
replenishment of the intracellular NAD pool. The development of 
many cancers is associated with increased NAMPT expression 
[5]. Cancer cells have a high rate of NAD turnover due to 
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their increased energy demand and a high activity of NAD- 
dependent enzymes, such as poly (ADP-ribose) polymerases 
(PARPs), mono-ADP ribosyltransferases (MARTs) and sirtuins, 
required for DNA repair, genome stability and proliferation 
[1,5]. Therefore, cancer cells are more susceptible to NAMPT 
inhibition than normal cells [6,7]. In previous studies, we found 
that NAMPT is released from hepatocytes [8] as well as 
differentially expressed and more enzymatically active in 
hepatocarcinoma cells compared to non-cancerous human 
hepatocytes [9]. Hepatocellular carci- noma (HCC) is the 
second leading cause of cancer-related deaths [10]. The only 
available proven systemic therapy for HCC is the multi-targeting 
kinase inhibitor sorafenib [11]. An effective second- line agent 
for patients with sorafenib failure or intolerance has yet to be 
identified. This has led to an intensive search for molecular 
pathways and novel compounds for the treatment and 
prevention of HCC. Targeting NAMPT activity and intracellular 
NAD content represents a novel therapeutic concept for HCC. The 
specific NAMPT inhibitor FK866 is a competitive inhibitor that 
was selected by an anticancer screening system differentiating 
acute cytotoxicity from growth inhibition [12,13]. FK866 has 
been evaluated in a broad variety of tumors, including solid 
tumors and leukemia [14e16] in vitro and in nude mouse 
xenografts [17e19], where FK866 was able to reduce or 
attenuate tumor growth. 
In HCC tissue, AMP-activated protein kinase (AMPK), a 
major regulator of cellular energy homeostasis that coordinates 
multiple metabolic pathways, has been shown to be 
dysregulated compared to normal tissue [20,21]. AMPK 
activity opposes tumor develop- ment and negatively regulates 
the Warburg effect (aerobic glycol- ysis) leading to suppression 
of tumor growth in vivo [20e22]. AMPK translates changes in 
glucose availability and fluctuation of energy to mammalian 
target of rapamycin (mTOR) and thereby acts as a master 
energy sensor to modulate cellular activities in response to 
energy stress [23,24]. mTOR, a serine/threonine protein kinase, 
has been observed to be increased in multiple human 
cancers, including HCC, where it is associated with less 
differentiated tu- mors, earlier tumor recurrence, and worse 
survival outcomes [25,26]. Inhibition of mTOR has proven 
efficacious in clinical trials [26,27]. Recently, there is great 
scientific interest in finding mo- lecular pathways and novel 
compounds that target AMPK/mTOR signaling as a new 
treatment option for HCC. 
Little is known about the interaction of NAMPT and AMPK/ 
mTOR signaling during the development of HCC. In this study, 
we investigated the effects of the NAMPT inhibitor FK866 on 
hep- atocarcinoma cells and non-cancerous human hepatocytes. 
We asked whether or not FK866-induced energy stress might 
activate AMPK and modify the mTOR signaling pathway and 
whether the observed effects could be rescued by the NAMPT 
enzyme product NMN. 
 
2. Material and methods 
 
2.1. Material 
 
Cell culture media, supplements and antibiotics were obtained 
from PAA (Cölbe, Germany) or Invitrogen (Karlsruhe, Germany). 
FK866, nicotinamide mononucleotide (NMN) and camptothecin 
were purchased from SigmaeAldrich (Munich, Germany). Etopo- 
side was purchased from Merck Millipore (Darmstadt, Germany). 
 
2.2. Hepatocarcinoma cell lines 
 
Huh7 cells (p53-mutated) and Hep3B cells (p53-deficient) 
were maintained in DMEM medium with high glucose or MEM 
medium, respectively. Media were supplemented with 10% fetal 
bovine serum (FBS),  2  mM  glutamine,  100 IU  penicillin  
and  100  mg/mL streptomycin. All cells were grown at 37 oC 
in a humidified atmosphere of 95% air and 5% CO2. 
 
2.3. Primary human hepatocytes 
 
Tissue samples from patients undergoing liver surgery at the 
University Medical Center Regensburg were used. Primary 
human hepatocytes (PHH) were isolated and cultivated as 
described recently [28]. Briefly, non-neoplastic tissue samples 
from liver re- sections were obtained from patients undergoing 
partial hepatec- tomy for metastatic liver tumors of colorectal 
cancer. PHHs were isolated using a modified two-step 
EGTA/collagenase perfusion procedure and plated on collagen 
coated dishes. Experimental procedures were performed 
according to the guidelines of the charitable state controlled 
foundation HTCR (Human Tissue and Cell Research, 
Regensburg, Germany), with the informed patient's consent 
approved by the local ethical committee of the University of 
Regensburg. All experiments involving human tissues and cells 
have been carried out in accordance to The Code of Ethics of 
the World Medical  Association  (Declaration  of  Helsinki).  
Cells  were seeded in Williams' Medium E containing 2 mM 
glutamine, 10-7 mol/L dexamethasone, 100 IU penicillin, 100 
mg/mL streptomycin and 10%FBS. All cells were grown at 37 
oC in a humidified atmo- sphere of 95% air and 5% CO2. 
 
2.4. Cell treatments 
 
FK866 was dissolved in DMSO to create a stock solution 
of 10 mM. NMN was dissolved in the appropriate medium for 
a stock solution of 100 mM. After 16 h serum starvation, cells 
were treated with the indicated concentration of FK866 alone 
or in combination with NMN [500 mM] for 24, 48 and 72 h. 
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2.5. Cell viability and apoptosis 
 
Cell viability analysis was conducted using the cell 
proliferation reagent WST-1 (Roche, Grenzach-Wyhlen, 
Germany) according to manufacturer's instructions. To examine 
the effects of FK866 on cell death, the number of dead cells 
was measured by FACS analysis at different time points (48 h, 
72 h) using the AnnexinV-FITC Apoptosis Detection Kit (BD 
Pharmingen™, Franklin Lakes, USA). Adherent and floating 
cells were analyzed according to manufac- turer's protocol. 
Samples were analyzed using a Beckton-Dickinson FACS LSRII. 
As positive control, apoptosis was induced via camp- 
tothecin [2 mM] and etoposide [85 mM] for 24 h. Annexin+ 
(An+)and 
double-stained An+/propidium iodide (PI+) cells were 
considered as dead cells. 
 
2.6. ATP measurement 
 
ATP levels were measured with the luminescent-based Cell- 
Titer-Glo® Luminescent Cell Viability Assay (Promega, 
Madison, USA) according to the manufacturer's protocol. 
 
2.7. Western Blot 
 
Protein extraction and Western Blot analysis were performed 
as described previously [9]. Primary antibodies used for 
immuno- blotting included anti-phospho-AMPKa(Thr172), anti-
AMPKa, anti- phospho-mTOR(Ser2448), anti-mTOR, anti-
tubulin, anti-phospho p70S6 kinase(Thr389), anti-p70S6 
kinase, anti-phospho-4E- BP1(Ser65), anti-4E-BP1, anti-
acetylated lysine (Cell Signaling, Beverly, MA, USA) and anti-
GAPDH (MerckMillipore, Schwalbach, Germany). Appropriate 
secondary antibodies were purchased from DAKO (Hamburg, 
Germany). Immunoblotting for GAPDH or tubulin was performed 
to verify equivalent amounts of loaded protein. Densitometric 
analysis was performed using ImageJ 1.41 Software (NIH, 
USA). 
 
2.8. NAMPT enzymatic activity 
 
NAMPT activity was measured by the conversion of 14C-
labeled nicotinamide to 14C-NMN using a method previously 
described [9,29]. Radioactivity of 14C-NMN was quantified in 
a liquid scintillation counter in counts per minute (cpm) (Wallac 
1409 DSA, PerkinElmer). NAMPT activity (cpm) was normalized 
to total protein concentration as measured by the BCA protein 
assay. 
 
2.9. NAD measurement 
 
Concentrations of NAD from whole-cell extracts were quantified 
by HPLC analysis using a SUPELCOSIL™ LC-18-T HPLC column 
(Sigma Aldrich) at a flow rate of 0.8 ml/min with 100% buffer 
A (potassium phosphate buffer pH 6.0) from 0 to 2 min, a linear 
gradient to 85% Buffer A/15% Buffer B (100% methanol) from 2 
to 5 min, 85% Buffer A/15% Buffer B from 5 to 10 min, a linear 
gradient to 100% Buffer A from 10 to 12 min and 100% Buffer 
A from 12 to 15 min. NAD was eluted as a sharp peak at 8 min 
and quantitated based  on  the  peak  area  compared  to  a  
standard  curve  and normalized to total protein concentration as 
measured by the BCA protein assay. 
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3. Results 
 
3.1. FK866-induced NAMPT inhibition significantly 
decreased NAD levels in human hepatocarcinoma cells 
which could be ameliorated by NMN administration 
 
We stimulated hepatocarcinoma cells with FK866 [10 nM] 
and found significantly reduced NAMPT activity (-74.9 ± 8.1% 
in Huh7 cells, -38.1 ± 3.7% in Hep3B cells) (Fig. 1A) which 
caused a sharp decline of NAD levels (Huh7 cells 3.3 ± 0.3 
mmol/g protein [con] vs. 0.3 ± 0.2 mmol/g protein [10 nM 
FK866]; Hep3B cells 2.2 ± 0.7 mmol/ 
g protein [con] vs. 0.2 ± 0.08 mmol/g protein [10 nM 
FK866]) (Fig. 1B). Co-treatment with NMN restored intracellular 
NAD levels in all tested cell lines (Fig. 1B). To investigate the 
sensitivity of non- cancerous human hepatocytes towards 
FK866, we used the same treatment conditions as for 
hepatocarcinoma cells and found that non-cancerous 
hepatocytes showed no significant reduction in NAMPT 
activity and NAD levels at 10 nM FK866 after 48 h 
(Supplement Fig. 1A,B). 
Emerging evidence suggests that the cellular acetylation state 
is associated with the energy state of a cell [30]. We could show 
that FK866-induced NAD depletion led to a decreased activity 
of NAD- 
 
 
 
 
Fig. 1. FK866 reduced NAMPT activity and NAD content and increased global acetylation of lysine residues. A) NAMPT activity and B) NAD content were measured 
after 24 h and were normalized to total protein amount in each sample (n ¼ 3). C) Western Blot analysis of acetylated lysine residues in lysates of Hep3B cells 
treated with FK866 [10 nM], a combination of FK866 + NMN or NMN alone for 48 h. GAPDH was used as loading control. Densitometric analysis of each lane 
was performed in four independent Western Blots (n ¼ 4). Cells stimulated with serum-free medium were used as control [con] and were set 1. Data are represented 
as mean ± SEM and statistical analysis was performed using one- way ANOVA and the Bonferroni post hoc test (*p < 0.05, **p < 0.01, ***p < 0.001 compared 
to serum-free medium control; #p < 0.05, ##p < 0.01, ###p < 0.001 compared to FK866 [10 nM]). 
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Fig. 2. FK866-induced NAMPT inhibition reduced cell viability and ATP content and induced delayed cell death in hepatocarcinoma cells. A) Cell viability of Huh7 
and Hep3B cells after 24 h was measured using WST1-reagent (n ¼ 4). ATP content after B) 48 h and C) 72 h treatment with 10 nM FK866 (n ¼ 3). Cells stimulated 
with serum-free medium were used as control [con] and were set 100%. D) AnnexinV-FITC/PI assay of Huh7 and Hep3B cells treated with FK866, FK866 + NMN or 
NMN alone for 72 h (n ¼ 3). Cells stimulated with serum-free medium were used as control [con] and were set 1. Representative dot plots of the AnnexinV-FITC/PI 
staining in Huh7 and Hep3B cells are shown including the percentage of viable, An+ and An+/PI+ -cells. Data are represented as mean ± SEM and statistical 
analysis was performed using one-way ANOVA and the Bonferroni post hoc test (*p < 0.05, **p < 0.01, ***p < 0.001 compared to serum-free medium control; 
#p < 0.05, ##p < 0.01, ###p < 0.001 compared to FK866 [10 nM]). 
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dependent lysine deacetylases as measured by an increased 
global acetylation of lysine residues (+1.9-fold, p < 0.001) 
(Fig. 1C). The administration of NMN abrogated the FK866-
induced hyper- acetylation of lysine residues (p < 0.001) (Fig. 
1C). 
 
3.2. NAMPT inhibition by FK866 reduced cell 
viability, induced energy stress and led to delayed 
cell death in human hepatocarcinoma cells 
 
We could detect a decreased cell viability in 
hepatocarcinoma cells (-49.4 ± 4.6% in Huh7 cells, -20.6 ± 
2.8% in Hep3B cells) (Fig. 2A) after 24 h of FK866 treatment. 
We wanted to investigate whether FK866-induced NAD 
depletion would result in a reduction of ATP generation and 
therefore would induce cellular energy stress in hepatocarcinoma 
cells. Time course studies revealed that ATP levels were lowered 
in Huh7 cells (-49.6 ± 9.5%, p < 0.01) and Hep3B cells (-
61.1 ±  6.8%, p < 0.001) after 48 h of treatment with 10 nM 
FK866 (Fig. 2B). The ATP levels further declined after 72 h in Huh7 
cells  (-90.2  ±  2.5%,  p  <  0.001)  and  Hep3B  cells (-
91.1 ± 1.5%, p < 0.001) (Fig. 2C). The co-administration of 
NMN could ameliorate ATP levels in Huh7 and Hep3B cells after 
48 and 72 h (Fig. 2B,C). After 72 h, subsequent to the drop of 
NAD levels, the effects of FK866 on cell death became evident 
when measuring 
An+/PI+-stained cells. Hep3B cells, a p53-deficient cell line, 
already 
displayed an increase in An+/PI+ cells after 48 h of FK866 
treatment (+1.8-fold, p < 0.01) (Supplement Fig. 2A) indicating 
that FK866- induced cell death did not depend on p53 function. 
Huh7 cells treated with FK866 [10 nM] for 72 h showed a 1.5-
fold increase in An+/PI+ cells compared to control cells (p < 
0.05) (Fig. 2D) whereas the number of An+/PI+ Hep3B cells 
increased further (+3.0-fold, p < 0.01). Co-stimulation with 
NMN ameliorated the induction of cell death in Huh7 cells (p 
¼ 0.09) and completely rescued FK866- induced cell death in 
Hep3B cells (p < 0.01) (Fig. 2D). 
 
3.3. Dysregulation of the AMPK/mTOR signaling 
pathway in hepatocarcinoma  cells  compared  to  
non-cancerous  hepatocytes 
 
Growing evidence suggests that mTOR and AMPK 
dysregulation play an important role in hepatocellular 
carcinogenesis [20,31]. Therefore, we compared the protein 
amount of mTOR and its downstream target p70S6 kinase 
and also AMPKa activation in non-cancerous primary human 
hepatocytes and hepatocarcinoma cells. An increased protein 
level of total mTOR and p70S6 kinase was found in 
hepatocarcinoma cells compared to non-cancerous 
hepatocytes (Fig. 3A). In contrast, AMPKa activation was 
enhanced in non-cancerous primary human hepatocytes (PHH) 
compared to Huh7 and Hep3B cells despite equal AMPKa 
total protein amount (Fig. 3A). This suggests that mTOR signaling 
and AMPKa activation are involved in metabolic adaptation 
of hep- atocarcinoma cells and might be interesting targets for 
prevention of cancer cell growth. 
 
3.4. FK866-induced energy stress activated AMPKa and 
led to inhibition of mTOR complex1 signaling in 
hepatocarcinoma cells 
 
To test the efficacy of FK866-induced NAD depletion to 
activate AMPKa and inhibit the mTOR signaling pathway, we 
measured the phosphorylation state of different members of the 
AMPK/mTOR complex1 cascade. FK866 treatment increased 
the phosphorylation of AMPKa at Thr172 (+3.3-fold, p < 0.01) 
in hepatocarcinoma cells (Fig. 3B). This was associated with a 
significant down regulation of phosphorylated mTOR (Ser2448) 
by -50.7 ± 0.1% (p < 0.05) and the phosphorylation of its 
down-stream target 70S ribosomal protein S6 kinase 
(p70S6K) (by -94.7 ± 2.4%, p < 0.001) and eukaryotic  
initiation  factor  4E  binding  protein  1  (4E-BP1)(by -30.0 ± 
.0.1%, p < 0.05) indicating reduced protein synthesis and cell 
growth (Fig. 3B). Co-treatment with NMN [500 mM] 
completely reversed the FK866-induced effects on AMPKa 
activa- tion and mTOR complex1 signaling inhibition suggesting 
that the NMN biosynthetic activity of NAMPT is relevant in 
mediating the effects of FK866. NMN alone had no impact on 
AMPKa activation and mTORC1 signaling in hepatocarcinoma 
cells (Fig. 3B). Non- cancerous human hepatocytes treated 
with equal amounts of FK866 for 48 h did not show significant 
changes in AMPKa acti- vation and mTOR phosphorylation 
(Supplement Fig. 1C) verifying their lower sensitivity to FK866. 
 
4. Discussion 
 
During malignant transformation the cellular metabolism un- 
dergoes multiple molecular and metabolic adaptations to 
support cell growth and survival. NAD is a key determinant in 
cancer cell biology as it is essential for redox reactions and key 
component of signaling pathways that regulate transcription, 
DNA repair, apoptosis and metabolism [1].  In mammals,  
NAMPT is a main regulator of the intracellular NAD pool [2,3]. 
Here, we investigated whether or not the NAMPT inhibitor, 
FK866, would affect intra- cellular NAD and ATP concentrations 
in hepatocarcinoma cells and consequently would be able to 
regulate the activity of the metabolic sensors AMPK and mTOR. 
Our study showed that FK866 rapidly reduced NAD levels in 
hepatocarcinoma cells and led to delayed ATP depletion which 
could be ameliorated by administration of NMN. Break down 
Published in final edited form as: Biochemical and Biophysical Research Communications 458 (2015) 334e340, 
http://dx.doi.org/10.1016/j.bbrc.2015.01.111 
 
7 
of ATP levels was associated with increased cell death. In 
contrast to another study [6], we demonstrated that FK866 
reduced NAMPT activity, depleted NAD and ATP content and 
induced cell death in p53-deficient Hep3B cells suggesting that 
FK866-mediated cell death does not depend on functional p53. 
Our results are in line with a study performed in chronic 
lymphocytic leukemia cells [14]. In our study, especially Hep3B 
cells showed a high sensitivity to FK866 and an increased 
number of dead cells occurred already after 48 h of FK866 
treatment. Interestingly, non- cancerous human hepatocytes 
subjected to the same FK866 treat- ment as hepatocarcinoma 
cells did not display reduced NAMPT activity and NAD 
content even at a FK866 concentration 10-fold of the  EC50  
(EC50  8.2  nM)  indicating  a  lower  sensitivity  of  non- 
cancerous cells to FK866. This has also been described for 
normal 
blood cells [6,7]. Therefore, FK866 represents an interesting 
com- pound in cancer cell therapy as it progressively exhausts 
NAD content in cells with a high NAD turnover that mainly 
rely on nicotinamide and the NAMPT-mediated NAD salvage 
pathway as source of NAD. Cancer cells have a significantly 
higher NAD turn- over than normal cells to sustain their rapid 
proliferation, relative genomic instability, permanently ongoing 
DNA repair, increased aerobic glycolysis and increased 
activity of NAD-dependent deacetylases [1,12,13]. This is in 
line with results of our previous study showing that the 
expression of SIRT1, a NAD-dependent deacetylase, was 
significantly higher in hepatocarcinoma cells than in non-
cancerous hepatocytes [9]. 
In this study we could demonstrate that NAMPT inhibition 
by FK866 led to a sharp decline of intracellular ATP levels and 
there- fore induced energy stress. As a key physiological 
energy sensor, AMPK is a major regulator of cellular energy 
homeostasis that co- ordinates multiple metabolic pathways to 
balance energy supply [24]. Several  studies have shown that 
AMPK activators exhibit inhibitory effects on cancer cell growth 
[32,33]. AMPK is known to phosphorylate and activate 
tuberous sclerosis complex (TSC)2, a negative regulator of 
mTOR [34]. Therefore, the AMPK/mTOR pathway serves as a 
signaling nexus for regulating cellular meta- bolism, energy 
homeostasis, and cell growth, and dysregulation of each 
pathway may contribute to the development of HCC [20,26].
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Fig. 3. Expression of mTOR and AMPK in hepatocarcinoma cells and non-cancerous human hepatocyes and its regulation by FK866. A) Western blot analysis of 
AMPK and mTOR expression in lysates of non-cancerous, primary human hepatocytes (PHH), Huh7 and Hep3B cells (n ¼ 3). B) Western blot analysis of the 
AMPK/mTORC1 signaling pathway in lysates of Huh7 cells treated with FK866 [10 nM], a combination of FK866 [10 nM]+NMN [500 mM] or NMN [500 mM] 
alone for 48 h (n ¼ 3). GAPDH was used as loading control. One representative blot out of 3 independent experiments is shown. Background-corrected densitometric 
values were normalized to control (serum-free medium). Data are represented as mean ± SEM and statistical analysis was performed using one-way ANOVA and 
the Bonferroni post hoc test (*p < 0.05, **p < 0.01, ***p < 0.001 compared to serum-free medium control; #p < 0.05, ##p < 0.01, ###p < 0.001 compared 
to FK866 [10 nM]). 
 
 
Since the discovery that the mTOR pathway is hyperactivated 
in many cancers including HCC [25,26,31,35], there is a great 
interest in finding molecular pathways and novel compounds 
that target AMPK/mTOR signaling as novel treatment option for 
HCC. We could show that components of the mTORC1 
cascade were significantly higher expressed in 
hepatocarcinoma cells than in non-cancerous hepatocytes. 
Additionally, our data revealed that the activation of AMPKa 
was significantly decreased in hepatocarcinoma cells. 
Reduced AMPK activity has also been detected in primary 
human breast cancer [36] and lymphoma [21] cells. Thus, a 
dysregulated AMPK activity may represent an important 
regulatory step during tumor initiation and progression, 
allowing cancer cells to gain a metabolic growth advantage 
by enhancing aerobic glycolysis (Warburg effect) [21]. We 
made the intriguing discovery that FK866 acts as an AMPK 
activator in cancer cells potentially through its ability to induce 
cellular energy stress. Activation of AMPKa was associated 
with a down regulation of the mTORC1 pathway. All FK866 
induced effects could be completely reversed by NMN sug- 
gesting that these effects were mediated by NAD. mTORC1 
inhibi- tion led to decreased activation of its two downstream 
targets, p70S6K and 4E-BP1. p70S6K and 4E-BP1 are major 
regulators of protein translation and cellular growth [35]. This 
contradicts a study performed in neuronal cells where FK866 or 
a NAMPT knock down was shown to reduce AMPK activation 
[37]. However, this can be explained by the use of non-cancerous 
neuronal cells compared to cancer cells in our study. 
In summary, our study showed the importance of the NAMPT- 
mediated NAD salvage pathway for energy homeostasis in 
hep- atocarcinoma cells. Furthermore, FK866-induced NAMPT 
inhibition led to activation of AMPK and inhibition of mTOR 
signaling sug- gesting a putative use of FK866 alone or as a 
chemotherapeutic sensitizing drug to reduce cancer cell growth. 
In every case of po- tential therapeutic use, administration of 
NMN as antidote may be useful to modulate or counteract 
FK866 toxicity. Only early stages of HCC are curable with 
today's treatment protocols, therefore new therapeutic strategies 
are urgently needed and NAMPT inhibition represents a 
potential novel treatment approach. 
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